|
Market Closed -
Other stock markets
|
After hours 20:00:00 | |||
| 119.52 USD | -2.82% |
|
116.38 | -2.63% |
| 07-31 | Argus Adjusts Price Target on Incyte to $140 From $115, Maintains Buy Rating | MT |
| 07-30 | JPMorgan Adjusts Price Target on Incyte to $120 From $110, Maintains Neutral Rating | MT |
"Total Return" performance includes dividend payments over the period, as if they were reinvested at 100%.
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
Sector Biopharmaceuticals
| Capi. | Sales Growth | Profitability | Finances | EV / Sales | P/E | |
|---|---|---|---|---|---|---|
 | 24.23B | |||||
| 76.15B | |||||
| 47.83B | |||||
| 48.89B | |||||
| 41.37B | - | ||||
| 29.99B |
- Stock Market
- Stocks
- INCY Stock
- Charts Incyte Corporation
- Sector Chart
Select your edition
All financial news and data tailored to specific country editions
